🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

TRADE: Initial dose escalation strategy for adj abemaciclib allowed majority of pts to reach target dose and resulted in fewer treatment discontinuation #ASCO25 #bcsm Erica Mayer OncoAlert Oncology Brothers

SERENA-6: Using Camizestrant to treat emerging ESR1m ahead of disease progression during 1st line therapy of HR+/HER2- mBC ⬆️mPFS1 16m vs 9.2m ⬇️Time to deterioration in QoL ⁉️PFS2 still immature but trend reassuring ❓OS New treatment strategy to optimize 1st line therapy? I

🚨Key question: “Is more time on treatment worth going through the testing process if it doesn’t help you live longer?” What a spectacular plenary discussion by Angie DeMichele, MD, MSCE, FASCO !!! #ASCO25 #bcsm OncoAlert Oncology Brothers

At #ASCO25 this morning, Yara Abdou (Yara Abdou, MD, MSCR), MD, MSCR, will present at the poster session: (Poster 120) Real-world analysis of characteristics and risk of recurrence in Black patients (pts) with HR+/HER2− early breast cancer eligible for NATALEE. ⌚️: 9 a.m. - 12 p.m. CT

DB09: T-DXd + pertuzumab vs THP in the 1st line setting for HER2+ MBC ⬆️mPFS 40.7m vs 26.9m (HR 0.56) ⬆️ORR ⬆️mDOR >3 yrs ⬆️CR 15% vs 8.5% No doubt this is a highly effective regimen—but the toxicity of prolonged T-DXd until progression shouldn’t be overlooked. PROs will be

DB09: Biomarkers of early progression on THP vs prolonged response will be key to selecting ideal candidates for upfront T-DXd. Precision upfront starts with knowing who needs more! Great discussion by Dr. Isaacs! #ASCO25 #bcsm Oncology Brothers OncoAlert

At #ASCO25, @YabdouMD reported Black pts with high-risk HR+/HER2 early breast cancer had higher recurrence risk + worse survival compared w/White pts, underscoring the urgent need to improve outcomes/address disparities. #BCSM

neoCARHP: phase 3 trial of de-escalated neoadjuvant THP with or without carboplatin in HER2+ EBC ➡️non-inferior pCR with THP with better tolerability ❓Survival outcomes #ASCO25 #bcsm OncoAlert

CompassHER2 pCR: 🔹 pCR rates with THP: ➡️ 44% overall (64% in ER-, 33% in ER+) 🔹 Higher pCR linked to: ➡️ ER 0 or ER+ ≤70% ➡️ HER2 IHC 3+ ➡️ Weekly paclitaxel (vs q3wk docetaxel) 🔹 HER2Dx score: ➡️ Helps predict pCR likelihood 🔹 Takeaway: ➡️ Clinicopathologic + molecular

ctDNA status is significantly associated with high residual nodal burden: Results from the I-SPY2 trial. #ASCO25 #bcsm

15-year SOFT/TEXT update: ➡️ 15-yr BCFI: +6.5% E+OFS vs T and +3.7% T+OFS vs T ➡️ No Chemo grp had high (> 94%) 15-yr DRFI and OS regardless of ET ➡️ Largest absolute benefits in 15-yr DRFI and OS with E+OFS vs T+OFS seen in G3 tumors or women < 40 yrs ➡️>=10% BCFI improvement

Excellent presentation by Paola Zagami, MD showing OFS + ET improved DFS and OS in a global cohort of young BRCA mutation carriers! Proud of you 👏🏼 👏🏼🤩 #ASCO25 #bcsm OncoAlert Matteo Lambertini, MD PhD

With synchronous publication in NEJM, Fatima Cardoso ABC Global Alliance shows Elinzanetant reduces vasomotor symptoms (hot flashes) for patients on ET with HR+ BC #ASCO25

Congrats to our faculty/trainees who received ASCO Conquer Cancer, the ASCO Foundation awards: @YabdouMD, Career Dev Award Chemtai Mungo,MD,MPH, Career Dev Award Yash Agrawal, MD, Young Investigator Award Jaewon Lee, MD, Young Investigator Award

📣 Powerful work by @YabdouMD at #ASCO25 exposing a critical reality: eligibility alone isn’t equity. In this real-world study, Black women with HR+/HER2− early breast cancer—eligible for ribociclib per NATALEE—still faced worse RFS, DRFS, and OS compared to White women. ⚖️

Join UNC's Assistant Professor of Medicine Yara Abdou, MD, MSCR on June 12 as she discusses racial inequities and HER2-Negative breast cancer. This group will fill up fast, so make sure you register today graspcancer.org/events/asco25-… #asco2025 #bcsm #registertoday #GRASPPosters #GRASPatASCO

Sign up for free to read our exclusive June web feature! 🔐 This feature explores the evolution of the HER2-positive #BreastCancer landscape, including data from the phase 3 neoCARHP study and the phase 2 CompassHER2 pCR trial. Yara Abdou, MD, MSCR Paolo Tarantino Jason A. Mouabbi MD

After saying goodbye to anthracyclines— are we ready to also drop the carbo for our patients with stage II HER2+ breast cancer? Check our this discussion with friends and superstar breast oncs Yara Abdou, MD, MSCR Jason A. Mouabbi MD — powered by OncLive.com

Fellows please consider taking this survey on important topic of barriers to sexual health counseling 👇🏼 UNC Hematology-Oncology Fellowship